Obesity's "big three" are top of mind these days, thanks to recent FDA panel rejections and upcoming FDA decision dates for Arena Pharmaceuticals Inc.'s Lorqess (lorcaserin) and Vivus Inc.'s Qnexa (phentermine/topiramate), as well as a pending panel for Orexigen Therapeutics Inc.'s Contrave (naltrexone SR/bupropion SR).